Panel discussion: advances in precision prevention and diagnostics

Who may this interest?

• Medical Oncologists
• Clinical trial coordinators
• Clinical trial investigators
• Translational cancer researchers
• Researchers/ scientists

Speakers

Apostolia Tsimberidou
Tenured Professor of Medicine
Department of Investigational Cancer Therapeutics at The University of Texas, MD Anderson Cancer Center (TX, USA)

Apostolia Tsimberidou, MD, PhD is a Tenured Professor of Medicine in the Department of Investigational Cancer Therapeutics at The University of Texas, MD Anderson Cancer Center (TX, USA). She pioneered the personalized medicine program in the Department of Investigational Cancer Therapeutics.

In 2007, she developed and led the IMPACT (Initiative for Personalized Medicine and Advanced Cancer Therapy) program. She demonstrated that identifying tumor specific molecular aberrations and selecting therapy based on tumor abnormalities of individual patients with advanced cancer is associated with better overall outcomes.

Her work has garnered extensive media coverage by ASCO, The Economist, the Wall Street Journal, the Bloomberg report and the Boston Globe. She has a substantial publication record with >300 articles in high-impact peer-reviewed journals, books, and book chapters for cutting-edge advances in medicine. She has received various prestigious awards and she has been invited as a keynote speaker at many international conferences.

Tsimberidou is committed to high-quality innovative research to accelerate the development and implementation of precision medicine in the field of oncology through innovative therapeutic approaches, education, and patient care.

 

Prasanth Reddy
Senior Vice President, Global Enterprise Head of Oncology
Labcorp (London, UK)

Reddy is board certified in internal medicine, medical oncology, and hematology. He has practiced medicine and served in leadership positions for more than 10 years in various clinical settings including academia, private practice, and managed care.

Reddy earned a bachelor’s degree in microbiology and psychology from Kansas State University (MO, USA), and he earned his medical degree from the University of Kansas Medical Center (MO, USA), where he also completed his internal medicine residency and clinical hematology and oncology fellowship.

Reddy obtained a master’s degree in public health through a National Institutes of Health Clinical Research Curriculum Award (K30) and is an alumnus of Harvard Business School (MA, USA). Additionally, he is a fellow of the American College of Physicians and is a Certified Physician Executive.

 

William Audeh, MD, MS
Chief Medical Officer

Agendia (CA, USA)

William Audeh, MD, MS, Chief Medical Officer at Agendia, is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles.

Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

 

Justin Moyers
Assistant Clinical Professor
Chao Family Comprehensive Cancer Center University of California Irvine Health (CA, USA)

Justin T. Moyers is board certified medical oncologist at the University of California, Irvine Medical Center (CA, USA) and an assistant clinical professor of medicine at UCI School of Medicine (CA, USA).

His clinical interests include skin cancers and sarcomas and research interests in developmental therapeutics and Phase I clinical trials along with the use of biomarkers and genomic data for patient selection. He currently serves as the ASCO Editorial Fellow for JCO Precision Oncology. Moyers received a B.S. in Chemistry from the University of Kansas (MO, USA) and subsequently completed medical school at the University of Kansas School of Medicine.

He performed his residency in internal medicine residency at Providence St. Vincent Medical Center, in Portland, Oregon followed by a fellowship in Hematology and Oncology at Loma Linda University Medical Center in Loma Linda, (CA, USA). Finally he completed a fellowship in the Department of Investigational Cancer Therapeutics (A Phase I Program) at the University of Texas MD Anderson Cancer Center (TX, USA).

 

Terri Conneran
KRAS Lung cancer patient
Founder of KRAS Kickers

After years of volunteering at school and church, when her youngest was in college, Terri began wondering what she will do with her extra time. It was a Stage 3 diagnosis of lung cancer than began to fill her days in January 2017.

A lung cancer diagnosis is overwhelming and terrifying, yet it was from connecting with others in a cancer battle that she found encouragement and strength. It took 3 years to learn the KRAS oncogene was known by the clinician since the first biopsy. Upon learning she has a diagnosis- a name of the cancer mutant, went out looking to connect with her ‘people’… others with the same driver. Unable to find an existing group began KRAS Kickers to join all people; with any KRAS mutant patients,care partners, doctors, and researchers together to kick cancer’s KRAS.

Globally empowering cancer patients believing that KRAS Knowledge + Research + Advocacy = Survivors. This community is where Hope Shared is Hope Multiplied.